Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2026)

Rigel Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $29.9 million for Q1 2026.

• In Q1 2026, Short term Debt rose 101.59% year-over-year to $29.9 million; the TTM figure through Mar 2026 stood at $29.9 million (up 101.59% YoY), while the FY2025 annual figure was $29.8 million, up 309.96% from the prior year.
• Short term Debt for Q1 2026 stood at $29.9 million, roughly flat from $29.8 million in the prior quarter.
• The five-year high for Short term Debt was $29.9 million in Q1 2026, with the low at $7.2 million in Q4 2023.
• The 4-year median for Short term Debt is $18.6 million (2025), against an average of $19.5 million.
• Peak annual rise in Short term Debt reached 309.96% in 2025, while the deepest fall reached 0.24% in 2025.
• Rigel Pharmaceuticals' Short term Debt stood at $7.2 million in 2023, then advanced by 0.59% to $7.3 million in 2024, then soared by 309.96% to $29.8 million in 2025, then advanced by 0.18% to $29.9 million in 2026.
• Business Quant data shows RIGL's Short term Debt at $29.9 million in Q1 2026, $29.8 million in Q4 2025, and $29.8 million in Q3 2025.